Abstract 4859: MFP-FePt-GO nanocomposite promotes radiosensitivity of non-small cell lung cancer via activating caspase system and impairing DNA damage repair

Abstract

Abstract Recent advances in nanomedicine provide promising alternatives for cancer treatment that may improve the survival and life quality of patients with cancer. A novel nanocomposite (MFP-FePt-GO) based on a lamellar-structure magnetic graphene oxide (GO) and polyethylene glycol drug delivery system was designed, synthesized and functionalized for co-delivery of metronidazole and 5-fluorouracil. The chemical synthesis efficiency was measured by Fourier transform infrared spectroscopy, X-ray photoelectron spectroscopy and energy dispersive X-ray spectroscope. The morphology, dispersion and sizes of this nanocomposite were also measured with transmission electron microscope. This new nanocomposite exhibited good solubility, stability and biocompatibility. While no severe allergies, liver and kidney damage or drug-related deaths were observed, MFP-FePt-GO promoted radiosensitivity of non-small cell lung cancer (NSCLC) cells both in vivo and in vitro. MFP-FePt-GO imrpvoed the effects of radiation through activation of the caspase system and impairment of DNA damage repair. This novel nanocomposite also induced a reactive oxygen species burst, which suppressed the antioxidant protein expression and induced cell apoptosis. Furthermore, MFP-FePt-GO prevented the migration and invasion of NSCLC cells. Taken together, MFP-FePt-GO showed a synergistic anti-tumor effect with radiation in eliminating the tumors. With good safety and efficacy, this novel nanocomposite might be a potential radiosensitive agent for NSCLC patients. Citation Format: Shan Peng, Yingming Sun, Yuan Luo, Shijing Ma, Yan Gong, Conghua Xie. MFP-FePt-GO nanocomposite promotes radiosensitivity of non-small cell lung cancer via activating caspase system and impairing DNA damage repair [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4859.